Table 1.
Systemic characteristics and single-kidney function in study groups at 16 weeks.
| Lean | MetS | MetS+RAS | MetS+RAS+EVs | MetS+RAS+IL10KD EVs | |
|---|---|---|---|---|---|
| Body weight (Kg) | 71.1±4.0 | 93.4±0.9* | 92.4±2.3* | 90.6±3.1* | 86.9±3.0* |
| MAP (mmHg) | 102.8±3.6 | 124.2±4.0* | 128.8±6.7* | 120.0±3.4* | 116.9±3.9* |
| Degree of stenosis (%) | 0 | 0 | 61.4±7.6* | 61.3±4.3* | 68.0±6.4* |
| Total cholesterol (mg/dl) | 82.5 (76.0–90.5) | 347.0 (330.0–517.5)* | 390.0 (336.0–426.0)* | 413.0 (315.5–529.8)* | 420.0 (323.5–534.0)* |
| Triglycerides (mg/dl) | 8.0 (5.8–11.3) | 14.0 (13.0–25.5)* | 13.0 (5.0–20.0)* | 14.5 (8.3–16.8)* | 13.0 (10.5–18.0)* |
| HDL cholesterol (mg/dl) | 47.0 (42.5–52.5) | 140.0 (110.5–167.0)* | 110.0 (98.0–172.0)* | 126.0 (106.0–166.8)* | 107.0 (104.0–154.0)* |
| LDL cholesterol (mg/dl) | 33.4±6.5 | 398.4±140.4* | 319.6±128.5* | 314.3±119.6* | 416.4±114.3* |
| Fasting insulin (μU/ml) | 0.4 (0.3–0.5) | 0.7 (0.7–0.8)* | 0.7 (0.7–0.8)* | 0.7 (0.7–0.8)* | 0.7 (0.7–0.8)* |
| HOMA-IR score | 0.6 (0.6–0.7) | 1.9 (1.4–1.9)* | 1.9 (1.8–2.0)* | 1.9 (1.7–2.0)* | 1.9 (1.8–2.0)* |
| Fasting glucose (mg/dl) | 129.5±36.1 | 116.2±22.7 | 112.1±27.6 | 103.5±28.3 | 124.8±36.7 |
| Serum creatinine (mg/dl) | 1.47±0.23 | 1.54±0.18 | 1.77±0.23*† | 1.45±0.37‡ | 1.92±0.19* |
| PRA (ng/ml/h) | 0.14±0.09 | 0.15±0.08 | 0.21±0.11 | 0.14±0.12 | 0.15±0.17 |
| Renal volume (ml) | 137.2±6.4 | 217.9±7.4* | 182.4±8.8*† | 207.4±29.1*‡ | 189.3±15.6* |
| RBF (ml/min) | 502.1±27.4 | 848.6±76.1* | 628.5±27.5*† | 866.1±104.1*‡ | 447.8±85.2†‡ |
| GFR (ml/min) | 76.0±4.0 | 142.6±7.3* | 100.3±7.1*† | 128.7±13.6*‡ | 82.7±12.5† |
IL10KD: Interleukin-10 knockdown; MAP: Mean arterial pressure; PRA: Plasma renin activity; HDL: high-density lipoprotein; LDL: low-density lipoprotein; HOMA-IR: homeostasis model assessment of insulin resistance, RBF: renal blood flow; GFR: glomerular filtration rate.
*
p<0.05 vs. Lean;
†
p<0.05 vs. MetS;
‡
p<0.05 vs. MetS+RAS